Literature DB >> 11160835

Mutant Caldesmon lacking cdc2 phosphorylation sites delays M-phase entry and inhibits cytokinesis.

S Yamashiro1, H Chern, Y Yamakita, F Matsumura.   

Abstract

Caldesmon is phosphorylated by cdc2 kinase during mitosis, resulting in the dissociation of caldesmon from microfilaments. To understand the physiological significance of phosphorylation, we generated a caldesmon mutant replacing all seven cdc2 phosphorylation sites with Ala, and examined effects of expression of the caldesmon mutant on M-phase progression. We found that microinjection of mutant caldesmon effectively blocked early cell division of Xenopus embryos. Similar, though less effective, inhibition of cytokinesis was observed with Chinese hamster ovary (CHO) cells microinjected with 7th mutant. When mutant caldesmon was introduced into CHO cells either by protein microinjection or by inducible expression, delay of M-phase entry was observed. Finally, we found that 7th mutant inhibited the disassembly of microfilaments during mitosis. Wild-type caldesmon, on the other hand, was much less potent in producing these three effects. Because mutant caldesmon did not inhibit cyclin B/cdc2 kinase activity, our results suggest that alterations in microfilament assembly caused by caldesmon phosphorylation are important for M-phase progression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160835      PMCID: PMC30580          DOI: 10.1091/mbc.12.1.239

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  38 in total

1.  Phosphorylation of smooth muscle caldesmon by mitogen-activated protein (MAP) kinase and expression of MAP kinase in differentiated smooth muscle cells.

Authors:  T J Childs; M H Watson; J S Sanghera; D L Campbell; S L Pelech; A S Mak
Journal:  J Biol Chem       Date:  1992-11-15       Impact factor: 5.157

2.  Biphasic activation of two mitogen-activated protein kinases during the cell cycle in mammalian cells.

Authors:  H Tamemoto; T Kadowaki; K Tobe; K Ueki; T Izumi; Y Chatani; M Kohno; M Kasuga; Y Yazaki; Y Akanuma
Journal:  J Biol Chem       Date:  1992-10-05       Impact factor: 5.157

3.  Characterization of mitotically phosphorylated caldesmon.

Authors:  Y Yamakita; S Yamashiro; F Matsumura
Journal:  J Biol Chem       Date:  1992-06-15       Impact factor: 5.157

4.  Characterization of cDNA clones encoding a human fibroblast caldesmon isoform and analysis of caldesmon expression in normal and transformed cells.

Authors:  R E Novy; J L Lin; J J Lin
Journal:  J Biol Chem       Date:  1991-09-05       Impact factor: 5.157

5.  Smooth muscle cell proliferation. Expression and kinase activities of p34cdc2 and mitogen-activated protein kinase homologues.

Authors:  M H Watson; S L Venance; S C Pang; A S Mak
Journal:  Circ Res       Date:  1993-07       Impact factor: 17.367

6.  Identification of mitogen-activated protein kinase phosphorylation sequences in mammalian h-Caldesmon.

Authors:  L P Adam; D R Hathaway
Journal:  FEBS Lett       Date:  1993-05-03       Impact factor: 4.124

7.  Mammal-specific, ERK-dependent, caldesmon phosphorylation in smooth muscle. Quantitation using novel anti-phosphopeptide antibodies.

Authors:  G D'Angelo; P Graceffa; C A Wang; J Wrangle; L P Adam
Journal:  J Biol Chem       Date:  1999-10-15       Impact factor: 5.157

8.  Regulation of vascular smooth muscle tone by caldesmon.

Authors:  H Katsuyama; C L Wang; K G Morgan
Journal:  J Biol Chem       Date:  1992-07-25       Impact factor: 5.157

Review 9.  Caldesmon.

Authors:  F Matsumura; S Yamashiro
Journal:  Curr Opin Cell Biol       Date:  1993-02       Impact factor: 8.382

10.  Localization of caldesmon and its dephosphorylation during cell division.

Authors:  N Hosoya; H Hosoya; S Yamashiro; H Mohri; F Matsumura
Journal:  J Cell Biol       Date:  1993-06       Impact factor: 10.539

View more
  18 in total

1.  Caldesmon tethers myosin V to actin and facilitates in vitro motility.

Authors:  Brian Nibbelink; Mark E Hemric; Joe R Haeberle
Journal:  J Muscle Res Cell Motil       Date:  2004       Impact factor: 2.698

2.  Phosphorylation of Caldesmon by PFTAIRE1 kinase promotes actin binding and formation of stress fibers.

Authors:  Wilson K C Leung; Arthur K K Ching; Nathalie Wong
Journal:  Mol Cell Biochem       Date:  2010-12-24       Impact factor: 3.396

Review 3.  Diversification of caldesmon-linked actin cytoskeleton in cell motility.

Authors:  Taira Mayanagi; Kenji Sobue
Journal:  Cell Adh Migr       Date:  2011-03-01       Impact factor: 3.405

4.  Caldesmon regulates axon extension through interaction with myosin II.

Authors:  Tsuyoshi Morita; Taira Mayanagi; Kenji Sobue
Journal:  J Biol Chem       Date:  2011-12-09       Impact factor: 5.157

5.  A genetic screen for suppressors and enhancers of the Drosophila cdk1-cyclin B identifies maternal factors that regulate microtubule and microfilament stability.

Authors:  Jun-Yuan Ji; Marjan Haghnia; Cory Trusty; Lawrence S B Goldstein; Gerold Schubiger
Journal:  Genetics       Date:  2002-11       Impact factor: 4.562

Review 6.  Caldesmon as a therapeutic target for proliferative vascular diseases.

Authors:  Chi-Ming Hai
Journal:  Mini Rev Med Chem       Date:  2008-10       Impact factor: 3.862

7.  Activation of cyclin B1-Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis.

Authors:  Olivier Gavet; Jonathon Pines
Journal:  J Cell Biol       Date:  2010-04-19       Impact factor: 10.539

8.  Caldesmon regulates the motility of vascular smooth muscle cells by modulating the actin cytoskeleton stability.

Authors:  Qifeng Jiang; Renjian Huang; Shaoxi Cai; Chih-Lueh A Wang
Journal:  J Biomed Sci       Date:  2010-02-03       Impact factor: 8.410

9.  ARL4D recruits cytohesin-2/ARNO to modulate actin remodeling.

Authors:  Chun-Chun Li; Tsai-Chen Chiang; Tsung-Sheng Wu; Gustavo Pacheco-Rodriguez; Joel Moss; Fang-Jen S Lee
Journal:  Mol Biol Cell       Date:  2007-09-05       Impact factor: 4.138

Review 10.  Caldesmon and the regulation of cytoskeletal functions.

Authors:  C L Albert Wang
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.